Exploring the mechanism of action bitter melon in the treatment of breast cancer by network pharmacology

Core Tip

Core Tip: The phytochemicals and molecular processes in bitter melon that are thought to be involved in the therapy of breast cancer (BRCA) were investigated using network Pharmacology. Our research demonstrated that the anti-BRCA benefits of bitter melon are likely caused by negative regulation of transcription, cell differentiation, apoptosis, proteolysis, negative control of neuron apoptosis, and cell migration. Further discovered nine important pathways like phosphatidylinositol 3-kinase/protein kinase B signaling, transcriptional dysregulation, axon guidance, calcium signaling, focal adhesion, janus kinase-signal transducer and activator of transcription signaling, cyclic adenosine monophosphate signaling, mammalian target of rapamycin signaling, and phospholipase D signaling, are likely to be involved in the mechanism of action of bitter melon for the treatment of BRCA.